A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely ...
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...
Stocktwits on MSN
Regeneron’s drug combo fails to prove superiority over Merck’s Keytruda in melanoma
While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary ...
Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...
3don MSNOpinion
Lower drug prices won’t fix cancer care
As breakthrough drugs offer critical hope to patients, lawmakers should focus on shoring up the social safety net ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
On the second night of the largest annual European cancer conference, some 100 Merck scientists packed into Champeaux, a classic French restaurant, to break bread and share clinical wisdom. It was ...
The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results